Pharmacokinetic variability of anticancer agents - PubMed (original) (raw)
Review
doi: 10.1038/nrc1629.
Affiliations
- PMID: 15928675
- DOI: 10.1038/nrc1629
Review
Pharmacokinetic variability of anticancer agents
Samir D Undevia et al. Nat Rev Cancer. 2005 Jun.
Abstract
The translation of advances in cancer biology to drug discovery can be complicated by pharmacokinetic variation between individuals and within individuals, and this can result in unpredictable toxicity and variable antineoplastic effects. Previously unrecognized variables (such as genetic polymorphisms) are now known to have a significant impact on drug disposition. How can the pharmacokinetic variability of anticancer agents be reduced? This will require the understanding of correlations between pharmacokinetics and treatment outcomes, the identification of relevant patient parameters, mathematical modelling of individual and population pharmacokinetics, and the development of algorithms that will tailor doses to the individual patient.
Similar articles
- The importance of pharmacokinetic limited sampling models for childhood cancer drug development.
Panetta JC, Iacono LC, Adamson PC, Stewart CF. Panetta JC, et al. Clin Cancer Res. 2003 Nov 1;9(14):5068-77. Clin Cancer Res. 2003. PMID: 14613983 Review. - Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.
Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H, Kearns C, Stute N, Crom WR, Evans WE. Rodman JH, et al. Semin Oncol. 1993 Feb;20(1):18-29. Semin Oncol. 1993. PMID: 8475406 Review. - Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).
Knoester PD, Underberg WJ, Beijnen JH. Knoester PD, et al. Anticancer Res. 1993 Sep-Oct;13(5C):1795-808. Anticancer Res. 1993. PMID: 8267385 Review. - Interpreting disparate responses to cancer therapy: the role of human population genetics.
Maitland ML, DiRienzo A, Ratain MJ. Maitland ML, et al. J Clin Oncol. 2006 May 10;24(14):2151-7. doi: 10.1200/JCO.2005.05.2282. J Clin Oncol. 2006. PMID: 16682733 Review. - Improving the use of anticancer drugs: clinical pharmacokinetic approaches.
Collins JM. Collins JM. Isr J Med Sci. 1988 Sep-Oct;24(9-10):483-7. Isr J Med Sci. 1988. PMID: 3204004
Cited by
- Evaluation of nine formulas for estimating the body surface area of children with hematological malignancies.
Wu Q, Zhou Y, Fan X, Ma H, Gu W, Sun F. Wu Q, et al. Front Pediatr. 2022 Sep 7;10:989049. doi: 10.3389/fped.2022.989049. eCollection 2022. Front Pediatr. 2022. PMID: 36160791 Free PMC article. - Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.
Khurana V, Minocha M, Pal D, Mitra AK. Khurana V, et al. Drug Metabol Drug Interact. 2014;29(3):179-90. doi: 10.1515/dmdi-2013-0062. Drug Metabol Drug Interact. 2014. PMID: 24643910 Free PMC article. - Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets.
De Silva SF, Alcorn J. De Silva SF, et al. Pharmaceuticals (Basel). 2019 May 5;12(2):68. doi: 10.3390/ph12020068. Pharmaceuticals (Basel). 2019. PMID: 31060335 Free PMC article. Review. - Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, Cho JY, Yu KS, Shin SG, Paick JS, Jang IJ. Kim BH, et al. Br J Clin Pharmacol. 2008 Jun;65(6):848-54. doi: 10.1111/j.1365-2125.2008.03107.x. Epub 2008 Mar 3. Br J Clin Pharmacol. 2008. PMID: 18318773 Free PMC article. Clinical Trial. - Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.
Khurana V, Minocha M, Pal D, Mitra AK. Khurana V, et al. Drug Metabol Drug Interact. 2014;29(4):249-59. doi: 10.1515/dmdi-2014-0014. Drug Metabol Drug Interact. 2014. PMID: 24807167 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources